# Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab

> **NCT04264884** · — · APPROVED_FOR_MARKETING · sponsor: **Janssen Research & Development, LLC**

## Conditions studied

_None listed._

## Interventions

- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT04264884
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2020-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04264884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04264884, "Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04264884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*